arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

BioNexus Gene Lab Corp

BGLC
$1.58 ▲ +0.26 (+19.70%) at close
Healthcare ·Services-Medical Laboratories ·USServices-Medical Laboratories
9 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

BioNexus Gene Lab Corp faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth -21.9%
Op. Margin -39.9%
ROIC -34.4%
FCF / Share
Trailing P/E
Price / Book 0.4x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

9-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$7.42M
↓ -21.9%
Net Income Profit after all expenses
$-2.98M
↓ -86.7%
Operating Margin Operating profit as % of sales
-39.9%
↓ -141.3% 6th
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
7
Returns
21
Financial Health
7
Cash Quality
45

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 34 quarters